Microbial Bioactives
Microbial Bioactives | Online ISSN 2209-2161
295
Citations
189.6k
Views
157
Articles
Volume 9 Number 1 2026
REVIEWS (Open Access)
Clostridioides difficile Infection: Emerging Challenges and the Rise of Microbiome-Targeted Therapeutics
Wafaa Naser Radhi 1*
Microbial Bioactives 9 (1) 1-8 https://doi.org/10.25163/microbbioacts.9110623
Submitted: 09 January 2026 Revised: 01 March 2026 Accepted: 06 March 2026 Published: 08 March 2026
Abstract
Clostridioides difficile infection (CDI) continues to represent a major global healthcare challenge, driven by increasing incidence, high recurrence rates, and the emergence of hypervirulent strains. Traditionally considered an antibiotic-associated infection, CDI is now recognized as a complex disease shaped by interactions among microbial ecology, host immunity, and pathogen virulence. Conventional treatments, including metronidazole, vancomycin, and fidaxomicin, primarily target vegetative bacterial cells but do not fully eradicate dormant spores or restore the disrupted intestinal microbiome. As a result, recurrence occurs in a substantial proportion of patients, highlighting the limitations of antibiotic-centered management strategies. Recent advances in microbiome research have shifted attention toward ecological restoration of the gut microbial community as a key therapeutic objective. Evidence from clinical trials and meta-analyses demonstrates that microbiome-targeted interventions—particularly fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs)—can significantly reduce recurrence by restoring microbial diversity and reestablishing colonization resistance. These therapies promote functional recovery of microbial metabolism, including bile acid transformation pathways that inhibit C. difficile spore germination. Adjunctive approaches are also emerging, such as monoclonal antibodies targeting toxin B, nanoparticle-based drug delivery systems, and synthetic antimicrobial polymers designed to suppress toxin activity and prevent spore outgrowth. Collectively, these developments suggest a paradigm shift in CDI management—from pathogen eradication alone to integrated strategies that restore microbial ecosystem stability. Understanding the dynamic interactions between host immunity, microbial community structure, and bacterial virulence factors will be essential for developing next-generation therapies. Future research should focus on optimizing microbiome-based interventions, improving therapeutic standardization, and evaluating long-term safety to establish sustainable and personalized treatment strategies for CDI.
Keywords: Clostridioides difficile infection; microbiome restoration; fecal microbiota transplantation; live biotherapeutic products; recurrent CDI
References
Abeyawardhane, D. L., Godoy-Ruiz, R., Adipietro, K. A., Varney, K. M., Rustandi, R. R., Pozharski, E., & Weber, D. J. (2021). The importance of therapeutically targeting the binary toxin from Clostridioides difficile. International Journal of Molecular Sciences, 22(6), 2926. https://doi.org/10.3390/ijms22062926
Abt, M. C., Lewis, B. B., Caballero, S., Xiong, H., Carter, R. A., Sušac, B., et al. (2015). Innate immune defenses mediated by two ILC subsets are critical for protection against acute Clostridium difficile infection. Cell Host & Microbe, 18(1), 27–37. https://doi.org/10.1016/j.chom.2015.06.011
Allegretti, J. R., Kearney, S., Li, N., Bogart, E., Bullock, K., Gerber, G. K., et al. (2016). Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Alimentary Pharmacology & Therapeutics, 43(11), 1142–1153. https://doi.org/10.1111/apt.13616
Amin, R. B., Setu, S. N., Mia, R. (2025). "Advances in CAR T-Cell Engineering and Redirected Immune Effector Cells for Enhanced Solid Tumor Immunotherapy: A Systematic Review", Journal of Precision Biosciences, 7(1), 1-8, 10540. https://doi.org/10.25163/biosciences.7110540
Babakhani, F., Bouillaut, L., Gomez, A., Sears, P., Nguyen, L., & Sonenshein, A. L. (2012). Fidaxomicin inhibits spore production in Clostridium difficile. Clinical Infectious Diseases, 55(Suppl. 2), S162–S169. https://doi.org/10.1093/cid/cis453
Berenson, C. S., Lashner, B., Korman, L. Y., Hohmann, E., Deshpande, A., Louie, T. J., Sims, M., Pardi, D., Kraft, C. S., Wang, E. E. L., et al. (2023). Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic. Clinical Infectious Diseases, 77(11), 1504–1510. https://doi.org/10.1093/cid/ciad448
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009). Introduction to meta-analysis. Wiley. https://doi.org/10.1002/9780470743386
Chen, Y.-H., Li, T.-J., Tsai, B.-Y., Chen, L.-K., Lai, Y.-H., Li, M.-J., et al. (2019). Vancomycin-loaded nanoparticles enhance sporicidal and antibacterial efficacy for Clostridium difficile infection. Frontiers in Microbiology, 10, 1141. https://doi.org/10.3389/fmicb.2019.01141
Cowardin, C. A., Buonomo, E. L., Saleh, M. M., Wilson, M. G., Burgess, S. L., Kuehne, S. A., et al. (2016). The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nature Microbiology, 1(11), 16108. https://doi.org/10.1038/nmicrobiol.2016.108
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. https://doi.org/10.1016/0197-2456(86)90046-2
Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634. https://doi.org/10.1136/bmj.315.7109.629
Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., et al. (2022). SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. The New England Journal of Medicine, 386(3), 220–229. https://doi.org/10.1056/NEJMoa2106516
Gerding, D. N., Kelly, C. P., Rahav, G., Lee, C., Dubberke, E. R., Kumar, P. N., et al. (2018). Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clinical Infectious Diseases, 67(5), 649–656. https://doi.org/10.1093/cid/ciy171
Gurung, B., Stricklin, M., & Wang, S. (2024). Gut microbiota–gut metabolites and Clostridioides difficile infection: Approaching sustainable solutions for therapy. Metabolites, 14(1), 74. https://doi.org/10.3390/metabo14010074
Hall, I. C., & O'Toole, E. (1935). Intestinal flora in new-born infants: With a description of a new pathogenic anaerobe, Bacillus difficilis. American Journal of Diseases of Children, 49(2), 390–402. https://doi.org/10.1001/archpedi.1935.01970020105010
Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2022). Cochrane handbook for systematic reviews of interventions (Version 6.3). Cochrane. http://www.training.cochrane.org/handbook
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560. https://doi.org/10.1136/bmj.327.7414.557
Hvas, C. L., Dahl Jørgensen, S. M., Jørgensen, S. P., Storgaard, M., Lemming, L., Hansen, M. M., et al. (2019). Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology, 156(6), 1324–1332.e3. https://doi.org/10.1053/j.gastro.2018.12.019
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021). Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73(7), e1029–e1044. https://doi.org/10.1093/cid/ciab718
Khanna, S., Sims, M., Louie, T. J., Fischer, M., LaPlante, K., Allegretti, J., et al. (2022). SER-109: An oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics, 11(9), 1234. https://doi.org/10.3390/antibiotics11091234
Lee, A., Yoo, J. S., & Yoon, E.-J. (2024). Gut microbiota and new microbiome-targeted drugs for Clostridioides difficile infections. Antibiotics, 13(10), 995. https://doi.org/10.3390/antibiotics13100995
Lee, C., Louie, T., Bancke, L., Guthmueller, B., Harvey, A., Feuerstadt, P., et al. (2023). Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: Data from five prospective clinical trials. Therapeutic Advances in Gastroenterology, 16, 17562848231174277. https://doi.org/10.1177/17562848231174277
Lee, W.-T., Wu, Y.-N., Chen, Y.-H., Wu, S.-R., Shih, T.-M., Li, T.-J., et al. (2017). Octahedron iron oxide nanocrystals prohibited Clostridium difficile spore germination and attenuated local and systemic inflammation. Scientific Reports, 7(1), 8124. https://doi.org/10.1038/s41598-017-08387-y
Liu, R., Suárez, J. M., Weisblum, B., Gellman, S. H., & McBride, S. M. (2014). Synthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowth. Journal of the American Chemical Society, 136(41), 14498–14504. https://doi.org/10.1021/ja506798e
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. The New England Journal of Medicine, 364(5), 422–431. https://doi.org/10.1056/NEJMoa0910812
Markantonis, J. E., Fallon, J. T., Madan, R., & Alam, M. Z. (2024). Clostridioides difficile infection: Diagnosis and treatment challenges. Pathogens, 13(2), 118. https://doi.org/10.3390/pathogens13020118
McSharry, S., Koolman, L., Whyte, P., & Bolton, D. (2021). Investigation of the effectiveness of disinfectants used in meat-processing facilities to control Clostridium sporogenes and Clostridioides difficile spores. Foods, 10(6), 1436. https://doi.org/10.3390/foods10061436
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Setu, S. N., Amin, R. B., & Mia, R. (2025). Benchmarking the Omics Revolution: A Comprehensive Review of Methodological Consistency and Clinical Readiness. Journal of Precision Biosciences, 7(1), 1-11. https://doi.org/10.25163/biosciences.7110539
Vitiello, A., Sabbatucci, M., Zovi, A., Salzano, A., Ponzo, A., & Boccellino, M. (2024). Advances in therapeutic strategies for the management of Clostridioides difficile infection. Journal of Clinical Medicine, 13(5), 1331. https://doi.org/10.3390/jcm13051331
Wang, P.-W., Lee, W.-T., Wu, Y.-N., & Shieh, D.-B. (2021). Opportunities for nanomedicine in Clostridioides difficile infection. Antibiotics, 10(8), 948. https://doi.org/10.3390/antibiotics10080948
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. The New England Journal of Medicine, 376(4), 305–317. https://doi.org/10.1056/NEJMoa1602615
Article metrics
View details
0
Downloads
0
Citations
35
Views
0
Save
Save
0
Citation
Citation
35
View
View
0
Share
Share